Furazone (Nitrofurazone) Ointment

Nitrofurazone is a synthetic nitrofuran-class antibacterial compound that has been used for decades as a topical wound treatment in veterinary medicine. Marketed under brand names including Furazone, Furacin, and NFZ Puffer, nitrofurazone ointment has historically been one of the most widely recognized topical antibacterial products in farm animal medicine, applied to surface wounds, burns, lacerations, and skin infections across virtually all livestock species. The compound's chemical name is 2-[(5-nitro-2-furanyl)methylene]hydrazinecarboxamide, and it belongs to the nitrofuran family of antibacterial agents, which also includes nitrofurantoin (used systemically in human urinary tract infections) and furazolidone (historically used in livestock and poultry).

The mechanism of action of nitrofurazone involves bacterial reduction of the nitro group on the furan ring, generating reactive intermediates that damage bacterial DNA, ribosomes, and other essential macromolecules. This multi-target mechanism produces bactericidal activity against a broad spectrum of gram-positive and gram-negative bacteria commonly associated with wound infections, including Staphylococcus aureus, Streptococcus species, Escherichia coli, Proteus species, Clostridium species, and Enterobacter aerogenes. The broad-spectrum activity and the difficulty of developing resistance through a single mutation (due to the compound's multiple intracellular targets) contributed to nitrofurazone's widespread adoption as a first-line topical wound treatment for much of the 20th century.

The regulatory status of nitrofurazone in food-producing animals has undergone a dramatic transformation that is central to understanding its current role in farm animal medicine. The FDA has prohibited the extralabel use of all nitrofuran drugs, including nitrofurazone, in food-producing animals in the United States. This prohibition is codified in 21 CFR 530.41(a) and reflects concerns about the carcinogenic and mutagenic potential of nitrofuran compounds and their tissue-bound metabolites. Unlike most drug restrictions that can be managed through withdrawal periods, the nitrofuran prohibition is absolute because nitrofuran metabolites bind irreversibly to tissue proteins and cannot be eliminated through any practical withdrawal period. This means that no amount of time between treatment and slaughter can ensure the absence of detectable residues.

Despite the prohibition on food animal use, nitrofurazone products remain legally available for use in companion animals and horses not intended for food. This continued availability creates a significant compliance challenge on farms and in mixed-use veterinary practices, as products originally purchased for horses or companion animals must never be applied to cattle, swine, sheep, goats, poultry, or any other animal destined for the human food supply. The presence of nitrofurazone ointment on a farm where food animals are raised creates a risk of inadvertent or intentional misuse, and regulatory authorities conduct residue surveillance that can detect nitrofuran metabolites at extremely low concentrations in animal tissues.

Before the FDA prohibition on food animal use, nitrofurazone ointment was one of the most versatile and commonly used topical antibacterial products in livestock medicine. Its broad-spectrum activity against wound-associated bacteria, combined with its ease of application and over-the-counter availability, made it a staple of the farm medicine cabinet. Understanding the historical indications for nitrofurazone in farm animals provides context for the regulatory changes that now restrict its use and helps producers appreciate why alternative products must be used in food-producing animals.

Wound management was the primary historical application of nitrofurazone in farm animals. The product was routinely applied to surgical incisions following castration, dehorning, and other routine procedures in cattle, sheep, and goats. Traumatic wounds from barbed wire fences, machinery, and animal interactions were dressed with nitrofurazone ointment to prevent bacterial colonization and promote healing. Hoof wounds, sole abscesses, and interdigital lesions in cattle received topical nitrofurazone as part of foot care protocols. Umbilical stump treatment in newborn calves, lambs, and kids frequently involved nitrofurazone application to prevent navel infections (omphalitis) that could lead to systemic septicemia and joint ill.

Burn treatment and skin graft management represented additional important historical uses. The soluble dressing formulation of nitrofurazone was specifically designed for application to burned tissue, where it provided a moist antibacterial environment conducive to epithelial regeneration. In livestock, thermal burns from barn fires, chemical burns from caustic substances, and friction burns from rope or equipment were treated with nitrofurazone dressings. The compound's ability to maintain antibacterial activity in the presence of blood, serum, and wound exudates contributed to its effectiveness in the challenging wound environment.

Topical treatment of superficial bacterial skin infections (pyoderma) and infected skin wounds in livestock also fell within nitrofurazone's historical indication profile. Mixed bacterial infections involving staphylococci, streptococci, and gram-negative organisms responded well to topical nitrofurazone application. The ointment base provided a protective moisture barrier over the wound surface while delivering the antibacterial agent directly to the infection site. NFZ Puffer, a powder formulation, allowed treatment of wounds in locations where ointment application was impractical, and was particularly popular for treating ear tick wounds and superficial fly-strike lesions.

The widespread historical use of nitrofurazone in food animals created deeply ingrained habits among livestock producers that have been slow to change even after the regulatory prohibition. Many producers who began farming before the ban was implemented remember nitrofurazone as an effective, convenient, and inexpensive wound treatment. Educational efforts by veterinarians, extension services, and regulatory agencies have been necessary to inform producers about the prohibition and the serious legal and economic consequences of using nitrofurazone in food-producing animals.

The prohibition of nitrofuran drugs in food-producing animals represents one of the most significant regulatory actions affecting livestock medication in the United States. The FDA's decision to ban all nitrofuran compounds from use in food animals was driven by extensive toxicological evidence demonstrating that nitrofuran metabolites are carcinogenic and mutagenic in laboratory animal studies. This regulatory action applies to all nitrofuran compounds, including nitrofurazone, furazolidone, nitrofurantoin, and furaltadone, and encompasses all routes of administration, including topical application.

The scientific basis for the nitrofuran prohibition centers on the unique metabolic fate of these compounds in treated animals. Nitrofuran drugs are metabolized to reactive intermediates that form covalent bonds with tissue proteins, creating bound residues that cannot be removed by cooking, processing, or any practical withdrawal period. These protein-bound metabolites persist in tissues for the life of the animal, and analytical methods can detect them at parts-per-billion concentrations long after the parent drug has been eliminated from the body. The carcinogenicity data from chronic feeding studies in rodents, combined with the persistent and irreversible nature of tissue-bound residues, led FDA to conclude that no safe residue level could be established for nitrofuran compounds in food animal tissues.

The legal framework for the nitrofuran prohibition is codified in the Code of Federal Regulations at 21 CFR 530.41(a), which specifically lists nitrofurans among the drugs prohibited from extralabel use in food-producing animals. This prohibition is absolute and cannot be overridden by a veterinary prescription, an extended withdrawal period, or any other mechanism available under the Animal Medicinal Drug Use Clarification Act (AMDUCA). Even topical application of nitrofurazone to a minor surface wound on a food animal constitutes a federal violation, regardless of whether the animal is weeks, months, or years away from slaughter. The prohibition applies equally to cattle, swine, sheep, goats, poultry, aquaculture species, and all other animals whose products enter the human food chain.

Enforcement of the nitrofuran prohibition is supported by sensitive analytical testing methods that can detect tissue-bound nitrofuran metabolites at concentrations as low as 0.5-1.0 parts per billion (ppb). The USDA Food Safety and Inspection Service (FSIS) includes nitrofuran metabolite testing in its National Residue Program, and positive findings trigger investigation, potential condemnation of the carcass, and regulatory action against the producer. The specific metabolites monitored include semicarbazide (SEM, the marker metabolite for nitrofurazone), 3-amino-2-oxazolidinone (AOZ, for furazolidone), and 1-aminohydantoin (AHD, for nitrofurantoin). Because these metabolites persist indefinitely in tissues, even a single topical application of nitrofurazone to a food animal can result in a positive residue finding at slaughter regardless of the intervening time period.

International regulatory perspectives on nitrofurans are generally aligned with the U.S. position, with most major livestock-producing and importing nations prohibiting nitrofuran use in food animals. The European Union, Canada, Australia, and many other countries have enacted similar bans based on the same toxicological concerns. The Codex Alimentarius Commission has not established maximum residue limits for nitrofurans, reflecting the international consensus that no safe level of nitrofuran residues in food can be defined. This global prohibition means that the presence of nitrofuran metabolites in animal products is a trade barrier, and positive findings can result in rejection of shipments and trade sanctions.

The pharmacological properties of nitrofurazone underpin both its antibacterial efficacy and the toxicological concerns that have led to its prohibition in food animals. Understanding the drug's mechanism of action, spectrum of activity, and metabolic fate provides essential context for appreciating why nitrofurazone was historically so effective as a topical wound treatment and why its use in food-producing animals poses unacceptable food safety risks.

Nitrofurazone exerts its antibacterial effects through enzymatic reduction of the 5-nitro group on the furan ring by bacterial nitroreductases. This reduction generates a series of reactive intermediates, including nitroso, hydroxylamine, and amino derivatives, that interact with multiple bacterial cellular targets. These reactive species cause oxidative damage to DNA through strand breakage and base modification, inhibit key metabolic enzymes, and disrupt ribosomal function, impairing protein synthesis. The multi-target nature of nitrofurazone's bactericidal mechanism makes the development of high-level resistance relatively difficult compared to antibiotics that act on a single molecular target, which historically contributed to the compound's sustained clinical efficacy over decades of use.

The spectrum of antibacterial activity of nitrofurazone encompasses a broad range of gram-positive and gram-negative organisms commonly encountered in wound infections. Susceptible gram-positive organisms include Staphylococcus aureus (including many methicillin-sensitive strains), Streptococcus pyogenes, Streptococcus agalactiae, and various Corynebacterium species. Susceptible gram-negative organisms include Escherichia coli, Proteus species, Klebsiella pneumoniae, Enterobacter aerogenes, and Salmonella species. Notably, Pseudomonas aeruginosa is generally resistant to nitrofurazone, which limits its utility in wounds colonized with this opportunistic pathogen. Anaerobic bacteria, including Clostridium species commonly associated with soil-contaminated wounds, are also susceptible to nitrofurazone, which was a valuable attribute for treating farm animal injuries.

The pharmacokinetics of topically applied nitrofurazone are relevant to both its therapeutic activity and its residue implications. When applied to intact skin, systemic absorption of nitrofurazone is minimal. However, application to open wounds, burns, or abraded skin results in measurable absorption through the damaged epithelial barrier. The absorbed compound undergoes extensive hepatic metabolism, primarily through nitroreduction, producing reactive metabolites that bind covalently to tissue proteins. These protein-bound metabolites represent the toxicologically significant residue because they persist in tissues long after the parent drug and free metabolites have been eliminated. The irreversible nature of this protein binding is the fundamental reason that no withdrawal period can assure the absence of detectable nitrofuran residues in tissues of treated food animals.

The toxicological profile of nitrofurazone that prompted the food animal prohibition includes evidence of carcinogenicity in chronic rodent feeding studies, mutagenicity in bacterial and mammalian cell genotoxicity assays, and the potential for reproductive toxicity at high doses. The protein-bound metabolite semicarbazide (SEM), which serves as the marker residue for nitrofurazone, has been independently evaluated for potential toxicity, though its significance is complicated by the fact that SEM can also be formed from non-drug sources, including the thermal degradation of azodicarbonamide (a food processing agent) and certain natural processes. Nevertheless, regulatory authorities have maintained the prohibition on nitrofuran use in food animals based on the weight of toxicological evidence and the precautionary principle.

While nitrofurazone is prohibited for use in food-producing animals, it remains a legally available and widely used topical antibacterial for companion animals and horses not intended for slaughter. The following application and dosage information pertains exclusively to these permitted uses and is included to provide complete pharmaceutical reference information. This information must not be applied to cattle, swine, sheep, goats, poultry, or any animal destined for the human food supply.

The standard formulation of nitrofurazone ointment contains 0.2% (2 mg/g) nitrofurazone in a water-soluble polyethylene glycol (PEG) base. The water-soluble base is preferred over petroleum-based ointments for wound applications because it does not trap heat or debris beneath the dressing and can be easily removed with water irrigation during wound cleaning. The ointment is applied directly to the wound surface in a thin, even layer sufficient to cover the entire affected area. Application frequency is typically once to twice daily, depending on the severity of the wound and the amount of wound exudate, with dressing changes performed at each application to remove accumulated exudate, debris, and spent ointment.

Wound preparation before nitrofurazone application follows standard wound care principles. The wound should be cleaned with sterile saline or a dilute antiseptic solution to remove gross contamination, debris, and necrotic tissue. Gentle debridement of devitalized tissue improves the efficacy of topical antibacterial treatment by removing the biological substrate that supports bacterial proliferation. After cleaning, the wound surface should be blotted dry (but not desiccated) before ointment application. For deep or cavitary wounds, nitrofurazone-impregnated gauze packing can be used to deliver the antibacterial agent to all wound surfaces, though packing should be loose enough to allow drainage.

The NFZ Puffer powder formulation provides an alternative delivery method for wounds where ointment application is impractical or where a dry wound environment is preferred. The powder is puffed directly onto the wound surface using the squeeze-bottle applicator, creating a light coating of antibacterial powder over the affected area. This formulation is particularly useful for wounds on the extremities, in ear canals, or in other locations where ointment would be difficult to retain. The powder formulation contains nitrofurazone in an inert carrier and provides the same antibacterial spectrum as the ointment formulation.

Duration of treatment with nitrofurazone should be guided by wound healing progression and clinical judgment. Treatment is typically continued until the wound demonstrates healthy granulation tissue formation, re-epithelialization is progressing, and signs of active infection (purulent discharge, erythema, swelling, heat, pain) have resolved. Prolonged treatment beyond the resolution of infection is generally unnecessary and may potentially delay wound healing if the ointment base interferes with the later stages of epithelial migration. If a wound fails to show improvement within 5-7 days of appropriate nitrofurazone treatment, reassessment of the wound, including culture and sensitivity testing, is warranted to identify resistant organisms or other factors impeding healing.

Topical nitrofurazone is generally well-tolerated when applied to wounds in permitted species, with a relatively low incidence of adverse reactions at the local application site. The compound has been used for decades with an established safety profile for topical use, though certain adverse effects have been documented that warrant awareness. It is important to note that the systemic toxicological concerns driving the food animal prohibition relate primarily to chronic internal exposure and tissue-bound metabolite accumulation rather than acute local effects of topical application.

Local adverse reactions at the site of topical nitrofurazone application include contact sensitization (allergic contact dermatitis), which manifests as redness, swelling, pruritus, and papulovesicular eruption surrounding the treated wound. Contact sensitization to nitrofurazone has been well-documented in human medicine and occurs in a percentage of individuals following repeated or prolonged exposure. In animals, contact sensitization is more difficult to recognize clinically but may be suspected when wound healing deteriorates rather than improves with continued treatment, or when perilesional inflammation worsens despite apparent infection control. If sensitization is suspected, nitrofurazone should be discontinued and an alternative topical antibacterial substituted.

Local irritation distinct from allergic sensitization can also occur, particularly in heavily contaminated wounds or on highly sensitive tissue surfaces. Some animals exhibit transient pain or discomfort immediately following application, evidenced by brief agitation, foot stamping (for limb wounds), or head shaking (for ear or facial wounds). This discomfort typically subsides within minutes and is generally not clinically significant. The water-soluble PEG base itself can cause tissue irritation if applied to deep wounds with significant serosal or synovial surface exposure, and PEG-based preparations should be used with caution on wounds that communicate with body cavities.

Systemic adverse effects from topical nitrofurazone application are rare when the compound is used on surface wounds at recommended rates. However, extensive application to large wound areas, particularly deep burns with compromised vascular barriers, can result in sufficient absorption to produce systemic effects. Systemic nitrofurazone toxicity, though extremely uncommon from topical use, can manifest as gastrointestinal disturbance, peripheral neuropathy (documented in humans), and hematological changes including hemolytic anemia in species with glucose-6-phosphate dehydrogenase deficiency. In practice, the risk of systemic toxicity from topical wound treatment is negligible when the product is used on appropriately sized wound areas and for appropriate durations.

Photosensitization has been reported rarely in association with nitrofurazone use, though this is more commonly a concern with systemic nitrofuran administration than with topical application. Animals with heavily treated wounds that are exposed to direct sunlight may theoretically experience enhanced photosensitivity in the perilesional skin, though clinically significant photosensitization from topical nitrofurazone is uncommon. Animals undergoing nitrofurazone wound treatment do not generally require sun protection beyond normal husbandry practices.

The absolute and overriding contraindication for nitrofurazone is its use in any food-producing animal in the United States. This prohibition encompasses all livestock species including cattle, swine, sheep, goats, poultry, rabbits raised for meat, aquaculture species, and any other animal whose meat, milk, eggs, or other products are intended for human consumption. The prohibition extends to all formulations (ointment, powder, solution) and all routes of topical application. There is no exception, no withdrawal period, and no veterinary authority that can authorize nitrofuran use in food animals under any circumstance. Violation of this prohibition constitutes a federal offense with potential civil and criminal penalties.

Beyond the food animal prohibition, nitrofurazone carries additional contraindications and precautions relevant to its use in permitted species. Known hypersensitivity to nitrofurazone or other nitrofuran compounds (nitrofurantoin, furazolidone) contraindicates use, as cross-sensitivity within the nitrofuran class is expected. Animals that have previously demonstrated contact sensitization to nitrofurazone should receive alternative topical antibacterial treatment. The polyethylene glycol base used in many nitrofurazone formulations should be used with caution on wounds that penetrate body cavities or expose large areas of peritoneum, synovium, or other serosal surfaces, as PEG absorption from these surfaces has been associated with renal toxicity in some clinical reports.

Renal function considerations apply to animals receiving extensive topical nitrofurazone treatment on large wound surfaces. Polyethylene glycol, the base solvent in most nitrofurazone ointment formulations, is primarily eliminated through renal excretion, and animals with pre-existing renal insufficiency may have impaired clearance of absorbed PEG. In human medicine, cases of renal failure have been reported following extensive application of PEG-based wound dressings to large burn surfaces. While comparable reports in veterinary patients are limited, prudent use dictates caution when applying nitrofurazone ointment to very large wound areas, particularly in animals with compromised renal function.

Storage and handling precautions include protecting nitrofurazone products from light, as the compound is photolabile and degrades upon prolonged exposure to ultraviolet radiation. The characteristic yellow color of nitrofurazone solution and ointment fades as the compound degrades, providing a visual indicator of potency loss. Products should be stored in their original opaque containers at controlled room temperature and used within the expiration period. Nitrofurazone-containing products should be stored securely and separately from medications intended for food animal use, with clear labeling to prevent accidental application to livestock.

Farm-level compliance measures are essential when nitrofurazone products are present on premises where food animals are raised. Best practice dictates that nitrofurazone should not be stored in livestock treatment areas, medicine cabinets, or chute-side supply boxes where it could be mistakenly grabbed for use on cattle, swine, or other food animals. If nitrofurazone is maintained on the farm for horse use, it should be stored separately in a clearly designated equine or companion animal treatment area with prominent labeling indicating its prohibition in food animals. Some veterinarians and producers choose to avoid having nitrofurazone on the farm altogether, using alternative topical antibacterials for all species to eliminate the risk of inadvertent food animal exposure.

The prohibition of nitrofurazone in food-producing animals has necessitated the adoption of alternative topical wound management products and strategies that provide effective antibacterial protection without the residue concerns associated with nitrofuran compounds. Numerous alternatives are available that offer comparable or superior wound care outcomes while maintaining full regulatory compliance. Producers and veterinarians should be familiar with these options to ensure that food animal wound management meets both therapeutic and regulatory requirements.

Topical iodine-based products represent one of the most widely used alternatives to nitrofurazone for livestock wound care. Povidone-iodine (Betadine) solutions and ointments provide broad-spectrum antibacterial, antifungal, and antiviral activity with minimal tissue toxicity when used at appropriate concentrations. Dilute povidone-iodine solution (0.1-1.0%) is suitable for wound irrigation, while the ointment formulation provides sustained antibacterial activity on wound surfaces. Tincture of iodine (2-7%) is commonly used for navel dipping in newborn calves, lambs, and kids, replacing the historical use of nitrofurazone for this application. Iodine-based products do not carry food animal use restrictions and have no established slaughter withdrawal requirements at typical topical use concentrations.

Chlorhexidine-based wound products offer another effective alternative with excellent broad-spectrum antibacterial activity. Chlorhexidine gluconate (0.05-0.5% solutions) is used for wound irrigation and surface disinfection, providing persistent antibacterial activity through binding to tissue surfaces. Chlorhexidine is effective against gram-positive bacteria, many gram-negative organisms, and some fungi, making it suitable for the mixed bacterial populations typically found in livestock wounds. The compound has low tissue toxicity at appropriate dilutions and does not carry food animal use restrictions when used topically.

Topical wound sprays containing antimicrobial agents such as oxytetracycline (Terramycin spray), gentian violet, or scarlet oil provide convenient application methods for farm animal wound care. Oxytetracycline aerosol wound sprays are widely available over the counter and provide antibacterial coverage with clearly labeled withdrawal time requirements for food animals. These spray formulations are particularly practical for treating surgical sites, lacerations, and abrasions in cattle and other livestock, as they can be applied quickly without restraint in many situations. Blue-dye containing wound sprays have the additional advantage of visually marking treated areas, aiding in monitoring healing progress.

Silver-based wound products, including silver sulfadiazine cream and colloidal silver dressings, provide potent broad-spectrum antibacterial activity suitable for complex wound management. Silver sulfadiazine cream (1%) has been used extra-label in food animals under veterinary supervision, though producers must consult with their veterinarian regarding withdrawal time requirements, as silver sulfadiazine contains a sulfonamide component. Honey-based wound dressings, particularly medical-grade manuka honey products, have gained acceptance in veterinary wound care as evidence supporting their antibacterial and wound-healing properties has accumulated. These natural products offer an alternative approach that avoids pharmaceutical residue concerns entirely.

Wound management in food animals should also incorporate non-pharmacological strategies that reduce the need for topical antibacterials. Proper wound hygiene, including thorough irrigation with sterile saline or clean water, removal of contaminated and devitalized tissue, and protection of the wound from environmental contamination through appropriate bandaging or housing, forms the foundation of effective wound healing. Clean, well-ventilated housing for recovering animals, fly control measures during warmer months, and attention to nutritional status to support immune function and tissue repair all contribute to favorable wound outcomes without additional pharmacological intervention.

The analytical detection of nitrofuran metabolites in animal tissues has advanced significantly over the past two decades, and modern laboratory methods can identify residues at extraordinarily low concentrations that make concealment of nitrofurazone use in food animals effectively impossible. Understanding the sensitivity of residue testing and the legal framework governing violations provides important context for the absolute nature of the food animal prohibition and reinforces why compliance is both a legal obligation and a practical necessity.

The standard analytical method for detecting nitrofuran metabolites in animal tissues involves acid hydrolysis of tissue samples to release protein-bound metabolites, followed by derivatization and detection using liquid chromatography-tandem mass spectrometry (LC-MS/MS). This method targets the specific marker metabolites unique to each nitrofuran compound: semicarbazide (SEM) for nitrofurazone, 3-amino-2-oxazolidinone (AOZ) for furazolidone, 1-aminohydantoin (AHD) for nitrofurantoin, and 3-amino-5-methylmorpholino-2-oxazolidinone (AMOZ) for furaltadone. Detection limits for these methods are typically in the range of 0.5-1.0 parts per billion (ppb), meaning that even trace residues from a single minor topical treatment can be detected in tissue samples collected at slaughter.

The persistence of nitrofuran metabolites in tissues creates a residue detection window that extends indefinitely after treatment. Unlike conventional drug residues that deplete through metabolism and excretion over predictable timeframes, protein-bound nitrofuran metabolites persist for the life of the tissue protein to which they are attached. As tissue proteins turn over through normal metabolic processes, bound metabolites are gradually released, but new protein synthesis in the presence of residual drug can create newly bound metabolites. Practical studies have demonstrated that detectable nitrofuran metabolites can persist in tissues for months to years after a single treatment episode, depending on the extent of initial exposure and the sensitivity of the analytical method.

Legal consequences for nitrofuran violations in the United States can be severe and multifaceted. At the producer level, a positive nitrofuran residue finding at slaughter results in condemnation of the affected carcass and all associated products, creating direct financial loss. The USDA FSIS assigns the producer to intensified sampling status, requiring subsequent animals from the same operation to be tested before carcass release, creating delays and additional costs. Repeated violations can result in criminal prosecution under the Federal Food, Drug, and Cosmetic Act, with potential penalties including fines and imprisonment. The FDA Center for Veterinary Medicine may issue warning letters, seek injunctions, or pursue other enforcement actions against producers, veterinarians, or feed suppliers involved in prohibited nitrofuran use.

Veterinary professional consequences for facilitating or failing to prevent nitrofuran use in food animals can include disciplinary action by state veterinary licensing boards, exclusion from federal and state practice programs, and civil liability for economic damages suffered by clients whose animals produce positive residue findings. Veterinarians have a professional responsibility to educate their food animal clients about the nitrofuran prohibition, to ensure that nitrofuran products are not included in treatment protocols for food animals, and to recommend compliant alternatives for wound management. Documentation of client education regarding prohibited substances is a prudent practice management strategy that demonstrates professional diligence.